Oxford BioMedica plc  

(Public, LON:OXB)   Watch this stock  
Find more results for OXB
0.00 (0.00%)
Apr 17 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 2.20 - 2.20
52 week 1.30 - 3.80
Open 2.20
Vol / Avg. 357,326.00/1.12M
Mkt cap 31.16M*
P/E     -
Div/yield     -
EPS -0.01*
Shares 1.42B
Beta     -
Inst. own     -
Jun 23, 2014
Oxford BioMedica plc at Piper Jaffray Gene Therapy Conference Add to calendar
Jun 23, 2014
Oxford BioMedica plc at Biotechnology Industry Organization (BIO) International Convention Add to calendar
Jun 5, 2014
Oxford BioMedica PLC Annual General Meeting (Estimated) Add to calendar
May 15, 2014
Oxford BioMedica PLC Interim Management Statement (Estimated) Add to calendar
Apr 10, 2014
Preliminary 2013 Oxford BioMedica PLC Earnings Conference Call
Apr 10, 2014
Preliminary 2013 Oxford BioMedica PLC Earnings Release
Mar 26, 2014
Oxford BioMedica plc at Alliance for Regenerative Medicine RegenMed Investor Day
Feb 17, 2014
Oxford BioMedica plc at IPR Connections World Pharma Licensing Congress

Key stats and ratios

Q2 (Jun '13) 2012
Net profit margin -277.55% -112.56%
Operating margin -319.14% -135.21%
EBITD margin - -122.69%
Return on average assets -54.57% -34.56%
Return on average equity -69.44% -46.67%
Employees 83 -
CDP Score - -


Medawar Centre Robert Robinson Avenue The Oxford Science Park
Oxford, ENG OX4 4GA
United Kingdom - Map
+44-1865-783000 (Phone)
+44-1865-783001 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance


Oxford BioMedica plc (Oxford BioMedica) is a biopharmaceutical company developing gene-based medicines and therapeutic vaccines. The Company is evaluating product candidates for four ocular indications, including uveitis and three undisclosed genetic retinal diseases. The Company's technology platform includes a LentiVector gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a tumour antigen (5T4), which is a target for anti-cancer therapy. Its partnership with Sanofi comprises four LentiVector platform product candidates for four ocular indications: RetinoStat for wet age-related macular degeneration (AMD), StarGen for Stargardt disease, UshStat for Usher syndrome type 1B, and EncorStat for corneal graft rejection. Its manufacturing capabilities cover the entire product lifecycle; from pre-clinical development, to regulatory support, to all future stages of viral vector product clinical development.

Officers and directors

John Dawson Chief Executive Officer, Executive Director
Age: 53
Tim Watts Chief Financial Officer, Company Secretary, Executive Director
Age: 55
Peter Nolan Senior Vice President - Commercial Development, Executive Director
Age: 60
Madhu Davies Chief Medical Officer
Nicholas Rodgers Non-Executive Independent Chairman of the Board
Age: 54
Andrew J. Heath M.D., Ph.D. Non-Executive Deputy Chairman of the Board, Senior Independent Director
Age: 64
Martin Diggle Non-Executive Director
Age: 50
Paul Blake M.D. Non-Executive Independent Director
Age: 65